Clinical pharmacogenetic model to predict response of MTX monotherapy in patients with established rheumatoid arthritis after DMARD failure

Author： Fransen Jaap   Kooloos Wouter M   Wessels Judith AM   Huizinga Tom WJ   Guchelaar Henk-Jan   van Riel Piet LCM   Barrera Pilar  

Publisher： Future Medicine

ISSN： 1462-2416

Source： Pharmacogenomics, Vol.13, Iss.9, 2012-07, pp. : 1087-1094

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Related content

Testing pharmacogenetic indices to predict efficacy and toxicity of methotrexate monotherapy in a rheumatoid arthritis patient cohort

By  

Arthritis & Rheumatism, Vol. 62, Iss. 12, 2010-12 ,pp. : 3827-3829

John Wiley & Sons Inc

Access to resources Recommend Favorite

Leflunomide: a novel DMARD for the treatment of rheumatoid arthritis

By Alldred A.   Emery P.  

Expert Opinion on Pharmacotherapy, Vol. 2, Iss. 1, 2001-01 ,pp. : 125-137

Informa Healthcare

Access to resources Recommend Favorite

Iguratimod: novel DMARD promising for rheumatoid arthritis

By  

Inpharma, Vol. 1, Iss. 1450, 2004-01 ,pp. : 7-7

Adis International

Access to resources Recommend Favorite

Will Pharmacogenetics Predict Response to Therapies in Rheumatoid Arthritis?

By  

Current Pharmacogenomics, Vol. 4, Iss. 4, 2006-01 ,pp. : 307-319

Bentham Science Publishers

Access to resources Recommend Favorite

Durability and Rapidity of Response to Anakinra in Patients with Rheumatoid Arthritis

By Michael H. Schiff  

Drugs, Vol. 64, Iss. 22, 2004-01 ,pp. : 2493-2501

Adis International

Access to resources Recommend Favorite